

Kathryn A Ellis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1963299/publications.pdf>

Version: 2024-02-01

142
papers

14,096
citations

31976

53
h-index

21540

114
g-index

181
all docs

181
docs citations

181
times ranked

14555
citing authors

#	ARTICLE	IF	CITATIONS
1	Balance on the Brain: a randomised controlled trial evaluating the effect of a multimodal exercise programme on physical performance, falls, quality of life and cognition for people with mild cognitive impairmentâ€”study protocol. <i>BMJ Open</i> , 2022, 12, e054725.	1.9	4
2	Aggregation of Abnormal Memory Scores and Risk of Incident Alzheimerâ€™s Disease Dementia: A Measure of Objective Memory Impairment in Amnesic Mild Cognitive Impairment. <i>Journal of the International Neuropsychological Society</i> , 2021, 27, 146-157.	1.8	3
3	Combined physical and cognitive training for older adults with and without cognitive impairment: A systematic review and network meta-analysis of randomized controlled trials. <i>Ageing Research Reviews</i> , 2021, 66, 101232.	10.9	136
4	Assessment of the DTIâ€”ALPS Parameter Along the Perivascular Space in Older Adults at Risk of Dementia. <i>Journal of Neuroimaging</i> , 2021, 31, 569-578.	2.0	68
5	Dementia knowledge and associated factors among older Chinese adults: a cross-national comparison between Melbourne and Beijing. <i>International Psychogeriatrics</i> , 2021, 33, 1057-1067.	1.0	7
6	Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimerâ€™s Disease. <i>Journal of Alzheimer's Disease Reports</i> , 2021, 5, 443-468.	2.2	59
7	Ethnic Differences in Barriers and Enablers to Physical Activity Among Older Adults. <i>Frontiers in Public Health</i> , 2021, 9, 691851.	2.7	9
8	A Randomized Controlled Trial on the Effects of a 6-Month Home-Based Physical Activity Program with Individual Goal-Setting and Volunteer Mentors on Physical Activity, Adherence, and Physical Fitness in Inactive Older Adults at Risk of Cognitive Decline: The INDIGO Study. <i>Journal of Alzheimer's Disease</i> , 2021, 84, 207-226.	2.6	4
9	The Support Person's Preferences and Perspectives of Physical Activity Programs for Older Adults With Cognitive Impairment. <i>Frontiers in Public Health</i> , 2021, 9, 704561.	2.7	3
10	Effects of a physical activity intervention on brain atrophy in older adults at risk of dementia: a randomized controlled trial. <i>Brain Imaging and Behavior</i> , 2021, 15, 2833-2842.	2.1	1
11	Effect of a 24-month physical activity program on brain changes in older adults at risk of Alzheimer's disease: the AIBL active trial. <i>Neurobiology of Aging</i> , 2020, 89, 132-141.	3.1	28
12	Distinct effects of acute exercise and breaks in sitting on working memory and executive function in older adults: a three-arm, randomised cross-over trial to evaluate the effects of exercise with and without breaks in sitting on cognition. <i>British Journal of Sports Medicine</i> , 2020, 54, 776-781.	6.7	60
13	Combined effects of continuous exercise and intermittent active interruptions to prolonged sitting on postprandial glucose, insulin, and triglycerides in adults with obesity: a randomized crossover trial. <i>International Journal of Behavioral Nutrition and Physical Activity</i> , 2020, 17, 152.	4.6	16
14	Relationship of Established Cardiovascular Risk Factors and Peripheral Biomarkers on Cognitive Function in Adults at Risk of Cognitive Deterioration. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 163-171.	2.6	13
15	Effect of lean red meat combined with a multicomponent exercise program on muscle and cognitive function in older adults: a 6-month randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , 2020, 112, 113-128.	4.7	21
16	Impact of APOE-Î¼4 carriage on the onset and rates of neocortical AÎ²-amyloid deposition. <i>Neurobiology of Aging</i> , 2020, 95, 46-55.	3.1	32
17	Alcohol Use, Mental Health, and Functional Capacity as Predictors of Workplace Disability in a Cohort With Manifest Huntingtonâ€™s Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2020, 32, 235-243.	1.8	2
18	Baseline White Matter Is Associated With Physical Fitness Change in Preclinical Alzheimerâ€™s Disease. <i>Frontiers in Aging Neuroscience</i> , 2020, 12, 115.	3.4	7

#	ARTICLE	IF	CITATIONS
19	Physical activity for older Australians with mild cognitive impairment or subjective cognitive decline – A narrative review to support guideline development. <i>Journal of Science and Medicine in Sport</i> , 2020, 23, 913-920.	1.3	20
20	Targeted physical activity for older adults with mild cognitive impairment and subjective cognitive decline. <i>Medical Journal of Australia</i> , 2019, 210, 394.	1.7	6
21	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer’s disease. <i>Science Advances</i> , 2019, 5, eaau7220.	10.3	59
22	Morning exercise mitigates the impact of prolonged sitting on cerebral blood flow in older adults. <i>Journal of Applied Physiology</i> , 2019, 126, 1049-1055.	2.5	39
23	Effect of Morning Exercise With or Without Breaks in Prolonged Sitting on Blood Pressure in Older Overweight/Obese Adults. <i>Hypertension</i> , 2019, 73, 859-867.	2.7	33
24	A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer’s Disease: The AIBL Active-Study. <i>Journal of Alzheimer's Disease</i> , 2019, 70, S187-S205.	2.6	18
25	Depression and physical activity research in older age: An important gap to fill. <i>Psychology of Sport and Exercise</i> , 2019, 43, 1-3.	2.1	1
26	Physical activity for cognitive health: what advice can we give to older adults with subjective cognitive decline and mild cognitive impairment?. <i>Dialogues in Clinical Neuroscience</i> , 2019, 21, 61-68.	3.7	44
27	Amyloid burden and incident depressive symptoms in preclinical Alzheimer’s disease. <i>Journal of Affective Disorders</i> , 2018, 229, 269-274.	4.1	27
28	Alzheimer’s Disease: A Journey from Amyloid Peptides and Oxidative Stress, to Biomarker Technologies and Disease Prevention Strategies – Gains from AIBL and DIAN Cohort Studies. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 965-992.	2.6	96
29	Baseline Amnestic Severity Predicts Progression From Amnestic Mild Cognitive Impairment to Alzheimer Disease Dementia at 3 Years. <i>Alzheimer Disease and Associated Disorders</i> , 2018, 32, 190-196.	1.3	19
30	Trajectories of depressive and anxiety symptoms in older adults: a 6-year prospective cohort study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 405-413.	2.7	20
31	Predictors of Workplace Disability in a Premanifest Huntington’s Disease Cohort. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2018, 30, 115-121.	1.8	9
32	Interacting effects of exercise with breaks in sitting time on cognitive and metabolic function in older adults: Rationale and design of a randomised crossover trial. <i>Mental Health and Physical Activity</i> , 2018, 15, 11-16.	1.8	10
33	Trajectories of irregular word reading ability as a proxy for premorbid intelligence in Alzheimer’s disease, mild cognitive impairment, and healthy aging: A longitudinal study.. <i>Psychological Assessment</i> , 2018, 30, 1308-1316.	1.5	5
34	Sedentary behavior as a risk factor for cognitive decline? A focus on the influence of glycemic control in brain health. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 291-300.	3.7	111
35	A “Disease Severity Index” to identify individuals with Subjective Memory Decline who will progress to mild cognitive impairment or dementia. <i>Scientific Reports</i> , 2017, 7, 44368.	3.3	23
36	A randomized controlled trial of physical activity with individual goal-setting and volunteer mentors to overcome sedentary lifestyle in older adults at risk of cognitive decline: the INDIGO trial protocol. <i>BMC Geriatrics</i> , 2017, 17, 215.	2.7	10

#	ARTICLE	IF	CITATIONS
37	Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 169-183.	2.6	21
38	Associations of neighborhood environment with brain imaging outcomes in the Australian Imaging, Biomarkers and Lifestyle cohort. <i>Alzheimer's and Dementia</i> , 2017, 13, 388-398.	0.8	23
39	Implementation of subjective cognitive decline criteria in research studies. <i>Alzheimer's and Dementia</i> , 2017, 13, 296-311.	0.8	375
40	Subjective Memory Complaints in APOE ε4 Carriers are Associated with High Amyloid-β Burden. <i>Journal of Alzheimer's Disease</i> , 2016, 49, 1115-1122.	2.6	45
41	Acute effects of breaking up prolonged sitting on fatigue and cognition: a pilot study. <i>BMJ Open</i> , 2016, 6, e009630.	1.9	115
42	A Conceptualization of the Utility of Subjective Cognitive Decline in Clinical Trials of Preclinical Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2016, 60, 354-361.	2.3	37
43	Why attend a memory clinic? What do patients and their families want and/or expect?. <i>Australasian Journal on Ageing</i> , 2016, 35, 220-224.	0.9	9
44	Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2016, 12, 796-804.	0.8	135
45	Comparing the Performance of the HADS and the GDS-15 in the AIBL Study. <i>International Psychogeriatrics</i> , 2015, 27, 1577-1578.	1.0	3
46	Comparative analysis of the Cancer Council of Victoria and the online Commonwealth Scientific and Industrial Research Organisation FFQ. <i>British Journal of Nutrition</i> , 2015, 114, 1683-1693.	2.3	5
47	Phenomenological characterization of memory complaints in preclinical and prodromal Alzheimer's disease. <i>Neuropsychology</i> , 2015, 29, 571-581.	1.3	43
48	Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 175-187.	2.6	47
49	Subjective Cognitive Decline in Older Adults: An Overview of Self-Report Measures Used Across 19 International Research Studies. <i>Journal of Alzheimer's Disease</i> , 2015, 48, S63-S86.	2.6	317
50	Alterations in dorsal and ventral posterior cingulate connectivity in APOE ε4 carriers at risk of Alzheimer's disease. <i>BJPsych Open</i> , 2015, 1, 139-148.	0.7	5
51	Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study. <i>Journal of Alzheimer's Disease</i> , 2015, 46, 1079-1089.	2.6	28
52	The effects of a protein enriched diet with lean red meat combined with a multi-modal exercise program on muscle and cognitive health and function in older adults: study protocol for a randomised controlled trial. <i>Trials</i> , 2015, 16, 339.	1.6	34
53	Semi-automated hippocampal segmentation in people with cognitive impairment using an age appropriate template for registration. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 42, 1631-1638.	3.4	9
54	Amyloid-Related Memory Decline in Preclinical Alzheimer's Disease Is Dependent on APOE ε4 and Is Detectable over 18-Months. <i>PLoS ONE</i> , 2015, 10, e0139082.	2.5	22

#	ARTICLE	IF	CITATIONS
55	APOE ϵ 4 moderates amyloid-related memory decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1239-1244.	3.1	75
56	Comparison of MR-less PiB SUVR quantification methods. <i>Neurobiology of Aging</i> , 2015, 36, S159-S166.	3.1	96
57	Relationships Between Performance on the Cogstate Brief Battery, Neurodegeneration, and A β Accumulation in Cognitively Normal Older Adults and Adults with MCI. <i>Archives of Clinical Neuropsychology</i> , 2015, 30, 49-58.	0.5	40
58	Longitudinal cognitive decline in the AIBL cohort: The role of APOE ϵ 4 status. <i>Neuropsychologia</i> , 2015, 75, 411-419.	1.6	27
59	Amyloid- β 2, Anxiety, and Cognitive Decline in Preclinical Alzheimer Disease. <i>JAMA Psychiatry</i> , 2015, 72, 284.	11.0	160
60	Self and informant memory concerns align in healthy memory complainers and in early stages of mild cognitive impairment but separate with increasing cognitive impairment. <i>Age and Ageing</i> , 2015, 44, 1012-1019.	1.6	31
61	MR-Less Surface-Based Amyloid Assessment Based on 11C PiB PET. <i>PLoS ONE</i> , 2014, 9, e84777.	2.5	43
62	Effect of BDNF Val66Met on Memory Decline and Hippocampal Atrophy in Prodromal Alzheimer's Disease: A Preliminary Study. <i>PLoS ONE</i> , 2014, 9, e86498.	2.5	75
63	Age-related changes to the neural correlates of working memory which emerge after midlife. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 70.	3.4	15
64	Cerebral Microbleeds: A Review of Clinical, Genetic, and Neuroimaging Associations. <i>Frontiers in Neurology</i> , 2014, 4, 205.	2.4	176
65	Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. <i>British Journal of Psychiatry</i> , 2014, 204, 400-401.	2.8	29
66	Disclosing a dementia diagnosis: what do patients and family consider important?. <i>International Psychogeriatrics</i> , 2014, 26, 1263-1272.	1.0	21
67	Rates of diagnostic transition and cognitive change at 18-month follow-up among 1,112 participants in the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing (AIBL). <i>International Psychogeriatrics</i> , 2014, 26, 543-554.	1.0	37
68	Incidence of cerebral microbleeds in preclinical Alzheimer disease. <i>Neurology</i> , 2014, 82, 1266-1273.	1.1	125
69	Autobiographical narratives relate to Alzheimer's disease biomarkers in older adults. <i>International Psychogeriatrics</i> , 2014, 26, 1737-1746.	1.0	9
70	Physical activity program preferences and perspectives of older adults with and without cognitive impairment. <i>Asia-Pacific Psychiatry</i> , 2014, 6, 179-190.	2.2	44
71	A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, 844-852.	0.8	1,863
72	Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease. <i>Brain</i> , 2014, 137, 221-231.	7.6	182

#	ARTICLE	IF	CITATIONS
73	What is frontotemporal dementia?. Maturitas, 2014, 79, 216-219.	2.4	18
74	Influence of <i>BDNF</i> Val66Met on the relationship between physical activity and brain volume. Neurology, 2014, 83, 1345-1352.	1.1	58
75	Response to Comment on Moore et al. Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care 2013;36:2981-2987. Diabetes Care, 2014, 37, e151-e151.	8.6	4
76	Among Vitamin B12 Deficient Older People, High Folate Levels are Associated with Worse Cognitive Function: Combined Data from Three Cohorts. Journal of Alzheimer's Disease, 2014, 39, 661-668.	2.6	76
77	A β and cognitive change: Examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 743.	0.8	66
78	Influence of population versus convenience sampling on sample characteristics in studies of cognitive aging. Annals of Epidemiology, 2014, 24, 63-71.	1.9	61
79	An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation. Journal of Neuroimmunology, 2014, 273, 65-71.	2.3	87
80	Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 53-61.	0.8	114
81	Plasma Amyloid- β Levels are Significantly Associated with a Transition Toward Alzheimer's Disease as Measured by Cognitive Decline and Change in Neocortical Amyloid Burden. Journal of Alzheimer's Disease, 2014, 40, 95-104.	2.6	41
82	Amyloid- β Related Memory Decline is not Associated with Subjective or Informant Rated Cognitive Impairment in Healthy Adults. Journal of Alzheimer's Disease, 2014, 43, 677-686.	2.6	63
83	Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics, 2014, 15, S11.	2.6	67
84	Personal Memory Function in Mild Cognitive Impairment and Subjective Memory Complaints: Results from the Australian Imaging, Biomarkers, and Lifestyle (AIBL) Study of Ageing. Journal of Alzheimer's Disease, 2014, 40, 551-561.	2.6	10
85	Clinical utility of the cogstate brief battery in identifying cognitive impairment in mild cognitive impairment and Alzheimer's disease. BMC Psychology, 2013, 1, 30.	2.1	153
86	Increased Risk of Cognitive Impairment in Patients With Diabetes Is Associated With Metformin. Diabetes Care, 2013, 36, 2981-2987.	8.6	308
87	Predicting Alzheimer disease with β -amyloid imaging: Results from the Australian imaging, biomarkers, and lifestyle study of ageing. Annals of Neurology, 2013, 74, 905-913.	5.3	194
88	Longitudinal Analysis of Serum Copper and Ceruloplasmin in Alzheimer's Disease. Journal of Alzheimer's Disease, 2013, 34, 171-182.	2.6	46
89	A β amyloid, cognition, and <i>APOE</i> genotype in healthy older adults. Alzheimer's and Dementia, 2013, 9, 538-545.	0.8	51
90	Research and standardization in Alzheimer's trials: Reaching international consensus. , 2013, 9, 160-168.		20

#	ARTICLE	IF	CITATIONS
91	O4-07-01: Biomarker-based prediction of cognitive decline in 270 nondemented older individuals: Three-year follow-up results from the Australian Imaging Biomarkers and Lifestyle study of Aging (AIBL)., 2013, 9, P695-P695.		0
92	Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study. <i>Lancet Neurology</i> , The, 2013, 12, 357-367.	10.2	1,738
93	BDNF Val66Met, $A\beta$ amyloid, and cognitive decline in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2457-2464.	3.1	109
94	Cross-sectional and Longitudinal Analysis of the Relationship Between $A\beta$ Deposition, Cortical Thickness, and Memory in Cognitively Unimpaired Individuals and in Alzheimer Disease. <i>JAMA Neurology</i> , 2013, 70, 903.	9.0	170
95	Decline in Cognitive Function over 18 Months in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 34, 861-871.	2.6	42
96	Lack of reliable evidence for a distinctive β -related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study. <i>Brain</i> , 2013, 136, 2201-2216.	7.6	28
97	Rapid cognitive decline in Alzheimer's disease: a literature review. <i>International Review of Psychiatry</i> , 2013, 25, 650-658.	2.8	38
98	Three-Month Stability of the CogState Brief Battery in Healthy Older Adults, Mild Cognitive Impairment, and Alzheimer's Disease: Results from the Australian Imaging, Biomarkers, and Lifestyle-Rate of Change Substudy (AIBL-ROCS). <i>Archives of Clinical Neuropsychology</i> , 2013, 28, 320-330.	0.5	90
99	Enabling a multidisciplinary approach to the study of ageing and Alzheimer's disease: An update from the Australian Imaging Biomarkers and Lifestyle (AIBL) study. <i>International Review of Psychiatry</i> , 2013, 25, 699-710.	2.8	15
100	The association of $A\beta$ amyloid and composite cognitive measures in healthy older adults and MCI. <i>International Psychogeriatrics</i> , 2013, 25, 1667-1677.	1.0	24
101	Cognitive Decline in Adults with Amnesic Mild Cognitive Impairment and High Amyloid- β : Prodromal Alzheimer's Disease?. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 1167-1176.	2.6	34
102	Health professionals' and students' perceptions of elder abuse. <i>Australasian Journal on Ageing</i> , 2013, 32, 48-51.	0.9	10
103	Cognitive consequences of high $A\beta$ amyloid in mild cognitive impairment and healthy older adults: Implications for early detection of Alzheimer's disease.. <i>Neuropsychology</i> , 2013, 27, 322-332.	1.3	33
104	Rapid Decline in Episodic Memory in Healthy Older Adults with High Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2013, 33, 675-679.	2.6	62
105	Short term stability of verbal memory impairment in mild cognitive impairment and Alzheimer's disease measured using the International Shopping List Test. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 853-863.	1.3	13
106	Relationship between Memory Performance and β -Amyloid Deposition at Different Stages of Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2012, 10, 141-144.	1.4	43
107	Regional dynamics of amyloid- β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study. <i>Brain</i> , 2012, 135, 2126-2139.	7.6	222
108	A surface based approach for cortical thickness comparison between PiB+ and PiB- healthy control subjects. <i>Proceedings of SPIE</i> , 2012, , .	0.8	2

#	ARTICLE	IF	CITATIONS
109	Lifestyle and late life cognitive health: sufficient evidence to act now?. <i>International Psychogeriatrics</i> , 2012, 24, 683-688.	1.0	2
110	Predictors of rapid cognitive decline in Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of ageing. <i>International Psychogeriatrics</i> , 2012, 24, 197-204.	1.0	39
111	Stronger effect of amyloid load than <i>APOE</i> genotype on cognitive decline in healthy older adults. <i>Neurology</i> , 2012, 79, 1645-1652.	1.1	96
112	Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease. <i>Archives of Neurology</i> , 2012, 69, 1318.	4.5	348
113	Use of the CogState Brief Battery in the assessment of Alzheimer's disease related cognitive impairment in the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2012, 34, 345-358.	1.3	111
114	Protocol for a randomized controlled trial evaluating the effect of physical activity on delaying the progression of white matter changes on MRI in older adults with memory complaints and mild cognitive impairment: The AIBL Active trial. <i>BMC Psychiatry</i> , 2012, 12, 167.	2.6	40
115	Cortical surface mapping using topology correction, partial flattening and 3D shape context-based non-rigid registration for use in quantifying atrophy in Alzheimer's disease. <i>Journal of Neuroscience Methods</i> , 2012, 205, 96-109.	2.5	17
116	Memory improvements in elderly women following 16 weeks treatment with a combined multivitamin, mineral and herbal supplement. <i>Psychopharmacology</i> , 2012, 220, 351-365.	3.1	59
117	Homocysteine, Vitamin B12, and Folic Acid Levels in Alzheimer's Disease, Mild Cognitive Impairment, and Healthy Elderly: Baseline Characteristics in Subjects of the Australian Imaging Biomarker Lifestyle Study. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 909-922.	2.6	83
118	Independent contribution of temporal β -amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease. <i>Brain</i> , 2011, 134, 798-807.	7.6	132
119	IC-03-01: Dynamic of beta-amyloid deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a PiB-PET longitudinal study. , 2011, 7, S6-S6.		0
120	Advances in structural and molecular neuroimaging in Alzheimer's disease. <i>Medical Journal of Australia</i> , 2011, 194, S20-3.	1.7	5
121	A web-based normative data tool for assessing cognitive performance in healthy older Australians. <i>Medical Journal of Australia</i> , 2011, 194, S12-4.	1.7	3
122	Examining the nature of impairment in visual paired associate learning in amnesic mild cognitive impairment. <i>Neuropsychology</i> , 2011, 25, 752-762.	1.3	25
123	Cognition and beta-amyloid in preclinical Alzheimer's disease: Data from the AIBL study. <i>Neuropsychologia</i> , 2011, 49, 2384-2390.	1.6	139
124	Longitudinal assessment of β and cognition in aging and Alzheimer disease. <i>Annals of Neurology</i> , 2011, 69, 181-192.	5.3	730
125	Effects of Anticholinergic Drugs on Cognitive Function in Older Australians: Results from the AIBL Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 31, 173-178.	1.5	115
126	Association of Plasma A β Peptides with Blood Pressure in the Elderly. <i>PLoS ONE</i> , 2011, 6, e18536.	2.5	19

#	ARTICLE	IF	CITATIONS
127	Relationship between atrophy and β -amyloid deposition in Alzheimer disease. <i>Annals of Neurology</i> , 2010, 67, 317-324.	5.3	322
128	Plasma Amyloid- β^2 as a Biomarker in Alzheimer's Disease: The AIBL Study of Aging. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 1233-1242.	2.6	122
129	Larger temporal volume in elderly with high versus low beta-amyloid deposition. <i>Brain</i> , 2010, 133, 3349-3358.	7.6	130
130	Supervised method to build an atlas database for multi-atlas segmentation-propagation. <i>Proceedings of SPIE</i> , 2010, , .	0.8	0
131	Amyloid imaging results from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging. <i>Neurobiology of Aging</i> , 2010, 31, 1275-1283.	3.1	885
132	Addressing population aging and Alzheimer's disease through the Australian Imaging Biomarkers and Lifestyle study: Collaboration with the Alzheimer's Disease Neuroimaging Initiative. <i>Alzheimer's and Dementia</i> , 2010, 6, 291-296.	0.8	53
133	IC-01-03: Larger temporal volume in asymptomatic elderly with high versus low beta-amyloid deposition. , 2010, 6, S2-S3.		1
134	The Australian Imaging, Biomarkers and Lifestyle (AIBL) study of aging: methodology and baseline characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer's disease. <i>International Psychogeriatrics</i> , 2009, 21, 672-687.	1.0	661
135	The cognitive effects of modulating the glycine site of the NMDA receptor with high-dose glycine in healthy controls. <i>Human Psychopharmacology</i> , 2008, 23, 151-159.	1.5	15
136	Appearance modeling of 11C PiB PET images: Characterizing amyloid deposition in Alzheimer's disease, mild cognitive impairment and healthy aging. <i>NeuroImage</i> , 2008, 43, 430-439.	4.2	81
137	Tyrosine depletion alters cortical and limbic blood flow but does not modulate spatial working memory performance or task-related blood flow in humans. <i>Human Brain Mapping</i> , 2007, 28, 1136-1149.	3.6	12
138	Exploring the temporal dynamics of the spatial working memory n-back task using steady state visual evoked potentials (SSVEP). <i>NeuroImage</i> , 2006, 31, 1741-1751.	4.2	51
139	Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 175.	2.1	126
140	Muscarinic and nicotinic receptor modulation of object and spatial -back working memory in humans. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 81, 575-584.	2.9	108
141	Combined D1/D2 receptor stimulation under conditions of dopamine depletion impairs spatial working memory performance in humans. <i>Psychopharmacology</i> , 2005, 181, 771-780.	3.1	15
142	The pharmacology of human working memory. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 299-313.	2.1	81